JP2020122011A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020122011A5 JP2020122011A5 JP2020081948A JP2020081948A JP2020122011A5 JP 2020122011 A5 JP2020122011 A5 JP 2020122011A5 JP 2020081948 A JP2020081948 A JP 2020081948A JP 2020081948 A JP2020081948 A JP 2020081948A JP 2020122011 A5 JP2020122011 A5 JP 2020122011A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- antibody
- seq
- bone
- bone loss
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010065687 Bone loss Diseases 0.000 claims 19
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 125000003275 alpha amino acid group Chemical group 0.000 claims 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 12
- 102000019307 Sclerostin Human genes 0.000 claims 11
- 108050006698 Sclerostin Proteins 0.000 claims 11
- 210000000988 bone and bone Anatomy 0.000 claims 10
- 208000029725 Metabolic bone disease Diseases 0.000 claims 9
- 201000010099 disease Diseases 0.000 claims 9
- 206010049088 Osteopenia Diseases 0.000 claims 8
- 208000001132 Osteoporosis Diseases 0.000 claims 5
- 230000032683 aging Effects 0.000 claims 5
- 241000124008 Mammalia Species 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 3
- 210000003625 skull Anatomy 0.000 claims 3
- 208000011580 syndromic disease Diseases 0.000 claims 3
- 206010028851 Necrosis Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000007502 anemia Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 210000003054 facial bone Anatomy 0.000 claims 2
- 230000035876 healing Effects 0.000 claims 2
- 229910052500 inorganic mineral Inorganic materials 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000011707 mineral Substances 0.000 claims 2
- 230000017074 necrotic cell death Effects 0.000 claims 2
- 208000007848 Alcoholism Diseases 0.000 claims 1
- 201000000736 Amenorrhea Diseases 0.000 claims 1
- 206010001928 Amenorrhoea Diseases 0.000 claims 1
- 208000010392 Bone Fractures Diseases 0.000 claims 1
- 206010006956 Calcium deficiency Diseases 0.000 claims 1
- 206010061762 Chondropathy Diseases 0.000 claims 1
- 208000013725 Chronic Kidney Disease-Mineral and Bone disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- 206010015150 Erythema Diseases 0.000 claims 1
- 208000024720 Fabry Disease Diseases 0.000 claims 1
- 206010017076 Fracture Diseases 0.000 claims 1
- 208000015872 Gaucher disease Diseases 0.000 claims 1
- 102000018997 Growth Hormone Human genes 0.000 claims 1
- 108010051696 Growth Hormone Proteins 0.000 claims 1
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 claims 1
- 206010020850 Hyperthyroidism Diseases 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 208000017670 Juvenile Paget disease Diseases 0.000 claims 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 1
- 206010024229 Leprosy Diseases 0.000 claims 1
- 208000002720 Malnutrition Diseases 0.000 claims 1
- 208000030136 Marchiafava-Bignami Disease Diseases 0.000 claims 1
- 208000002678 Mucopolysaccharidoses Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000003926 Myelitis Diseases 0.000 claims 1
- 206010028570 Myelopathy Diseases 0.000 claims 1
- 208000009905 Neurofibromatoses Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010031264 Osteonecrosis Diseases 0.000 claims 1
- 208000013612 Parathyroid disease Diseases 0.000 claims 1
- 208000010067 Pituitary ACTH Hypersecretion Diseases 0.000 claims 1
- 208000020627 Pituitary-dependent Cushing syndrome Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 claims 1
- 206010053260 Secondary hyperthyroidism Diseases 0.000 claims 1
- 208000024799 Thyroid disease Diseases 0.000 claims 1
- 206010044688 Trisomy 21 Diseases 0.000 claims 1
- 208000026928 Turner syndrome Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 208000018839 Wilson disease Diseases 0.000 claims 1
- 208000008321 Winchester syndrome Diseases 0.000 claims 1
- 208000022567 adolescent idiopathic scoliosis Diseases 0.000 claims 1
- 201000007930 alcohol dependence Diseases 0.000 claims 1
- 231100000540 amenorrhea Toxicity 0.000 claims 1
- 239000001961 anticonvulsive agent Substances 0.000 claims 1
- 229960003965 antiepileptics Drugs 0.000 claims 1
- 230000004596 appetite loss Effects 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 230000037182 bone density Effects 0.000 claims 1
- 244000309466 calf Species 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 208000015100 cartilage disease Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 238000002316 cosmetic surgery Methods 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 231100000321 erythema Toxicity 0.000 claims 1
- 210000003743 erythrocyte Anatomy 0.000 claims 1
- 230000001815 facial effect Effects 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 230000005484 gravity Effects 0.000 claims 1
- 239000000122 growth hormone Substances 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 239000007943 implant Substances 0.000 claims 1
- 230000004968 inflammatory condition Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000009545 invasion Effects 0.000 claims 1
- 208000024884 ischemic bone disease Diseases 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 235000021266 loss of appetite Nutrition 0.000 claims 1
- 208000019017 loss of appetite Diseases 0.000 claims 1
- 230000001071 malnutrition Effects 0.000 claims 1
- 235000000824 malnutrition Nutrition 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 230000005906 menstruation Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 206010028093 mucopolysaccharidosis Diseases 0.000 claims 1
- 201000004931 neurofibromatosis Diseases 0.000 claims 1
- 230000002981 neuropathic effect Effects 0.000 claims 1
- 208000015380 nutritional deficiency disease Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 230000000399 orthopedic effect Effects 0.000 claims 1
- 230000011164 ossification Effects 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 208000002865 osteopetrosis Diseases 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 208000028169 periodontal disease Diseases 0.000 claims 1
- 208000001685 postmenopausal osteoporosis Diseases 0.000 claims 1
- 230000035935 pregnancy Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000002035 prolonged effect Effects 0.000 claims 1
- 201000006409 renal osteodystrophy Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 230000001256 tonic effect Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021195517A JP7361086B2 (ja) | 2005-05-03 | 2021-12-01 | スクレロスチンエピトープ |
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67758305P | 2005-05-03 | 2005-05-03 | |
| US60/677,583 | 2005-05-03 | ||
| US77684706P | 2006-02-24 | 2006-02-24 | |
| US60/776,847 | 2006-02-24 | ||
| US78224406P | 2006-03-13 | 2006-03-13 | |
| US60/782,244 | 2006-03-13 | ||
| US79264506P | 2006-04-17 | 2006-04-17 | |
| US60/792,645 | 2006-04-17 | ||
| US11/410,540 | 2006-04-25 | ||
| US11/410,540 US8003108B2 (en) | 2005-05-03 | 2006-04-25 | Sclerostin epitopes |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018147689A Division JP6858733B2 (ja) | 2005-05-03 | 2018-08-06 | スクレロスチンエピトープ |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021195517A Division JP7361086B2 (ja) | 2005-05-03 | 2021-12-01 | スクレロスチンエピトープ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020122011A JP2020122011A (ja) | 2020-08-13 |
| JP2020122011A5 true JP2020122011A5 (member.php) | 2020-11-26 |
| JP7010994B2 JP7010994B2 (ja) | 2022-02-10 |
Family
ID=36956127
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008510081A Active JP5680823B2 (ja) | 2005-05-03 | 2006-04-28 | スクレロスチンエピトープ |
| JP2014095921A Pending JP2014177470A (ja) | 2005-05-03 | 2014-05-07 | スクレロスチンエピトープ |
| JP2015192869A Active JP6158268B2 (ja) | 2005-05-03 | 2015-09-30 | スクレロスチンエピトープ |
| JP2017031654A Pending JP2017128583A (ja) | 2005-05-03 | 2017-02-23 | スクレロスチンエピトープ |
| JP2018147689A Active JP6858733B2 (ja) | 2005-05-03 | 2018-08-06 | スクレロスチンエピトープ |
| JP2020081948A Active JP7010994B2 (ja) | 2005-05-03 | 2020-05-07 | スクレロスチンエピトープ |
| JP2021195517A Active JP7361086B2 (ja) | 2005-05-03 | 2021-12-01 | スクレロスチンエピトープ |
Family Applications Before (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008510081A Active JP5680823B2 (ja) | 2005-05-03 | 2006-04-28 | スクレロスチンエピトープ |
| JP2014095921A Pending JP2014177470A (ja) | 2005-05-03 | 2014-05-07 | スクレロスチンエピトープ |
| JP2015192869A Active JP6158268B2 (ja) | 2005-05-03 | 2015-09-30 | スクレロスチンエピトープ |
| JP2017031654A Pending JP2017128583A (ja) | 2005-05-03 | 2017-02-23 | スクレロスチンエピトープ |
| JP2018147689A Active JP6858733B2 (ja) | 2005-05-03 | 2018-08-06 | スクレロスチンエピトープ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021195517A Active JP7361086B2 (ja) | 2005-05-03 | 2021-12-01 | スクレロスチンエピトープ |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US8003108B2 (member.php) |
| EP (6) | EP1891100A2 (member.php) |
| JP (7) | JP5680823B2 (member.php) |
| CA (1) | CA2607276C (member.php) |
| CY (2) | CY1118977T1 (member.php) |
| DK (2) | DK2301961T4 (member.php) |
| ES (5) | ES2624643T5 (member.php) |
| FI (2) | FI2301961T4 (member.php) |
| HR (2) | HRP20170679T4 (member.php) |
| HU (2) | HUE032092T2 (member.php) |
| LT (2) | LT2301961T (member.php) |
| MX (1) | MX348432B (member.php) |
| MY (1) | MY174493A (member.php) |
| PL (2) | PL2301961T5 (member.php) |
| PT (2) | PT2251351T (member.php) |
| SI (2) | SI2251351T2 (member.php) |
| WO (1) | WO2006119062A2 (member.php) |
Families Citing this family (108)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1044171B (zh) | 1998-11-27 | 2016-03-24 | Ucb Pharma S.A. | 增加骨矿化的组合物和方法 |
| AU2003276430A1 (en) | 2002-06-14 | 2003-12-31 | Stowers Institute For Medical Research | Wise/sost nucleic acid sequences and amino acid sequences |
| US7893218B2 (en) | 2003-06-16 | 2011-02-22 | Stowers Institute For Medical Research | Antibodies that specifically bind SOST peptides |
| US7585501B2 (en) | 2002-06-14 | 2009-09-08 | Stowers Institute For Medical Research | Compositions and methods for treating kidney disease |
| AU2004262640B2 (en) | 2003-06-16 | 2010-12-23 | Ucb Manufacturing, Inc. | Antibodies specific for sclerostin and methods for increasing bone mineralization |
| US7592429B2 (en) | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
| US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
| US8883162B2 (en) | 2005-10-19 | 2014-11-11 | Ibc Pharmaceuticals, Inc. | Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors |
| US9862770B2 (en) | 2005-10-19 | 2018-01-09 | Ibc Pharmaceuticals, Inc. | Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors |
| US20100226884A1 (en) | 2009-01-20 | 2010-09-09 | Immunomedics, Inc. | Novel Class of Monospecific and Bispecific Humanized Antibodies that Target the Insulin-like Growth Factor Type I Receptor (IGF-1R) |
| CN101479381B (zh) | 2006-03-31 | 2015-04-29 | 中外制药株式会社 | 调控抗体血液动力学的方法 |
| BRPI0712426B1 (pt) | 2006-06-08 | 2021-10-26 | Chugai Seiyaku Kabushiki Kaisha | Usos de um anticorpo anti-nr10/il-31ra com atividade neutralizante de nr10/il-31ra, de um fragmento e/ou um fragmento quimicamente modificado do anticorpo e de um agente |
| EP2097450A2 (en) * | 2006-11-10 | 2009-09-09 | Amgen Inc. | Antibody-based diagnostics and therapeutics |
| WO2008133722A2 (en) * | 2006-11-10 | 2008-11-06 | Ucb Pharma S.A. | Anti human sclerostin antibodies |
| EP4176884A1 (en) * | 2006-12-29 | 2023-05-10 | Ossifi-Mab LLC | Methods of altering bone growth by administration of sost or wise antagonist or agonist |
| WO2008101234A2 (en) * | 2007-02-16 | 2008-08-21 | Sloan-Kettering Institute For Cancer Research | Anti ganglioside gd3 antibodies and uses thereof |
| PT2131860E (pt) * | 2007-03-20 | 2014-03-04 | Lilly Co Eli | Anticorpos antiesclerostina |
| CL2008002775A1 (es) | 2007-09-17 | 2008-11-07 | Amgen Inc | Uso de un agente de unión a esclerostina para inhibir la resorción ósea. |
| WO2009041613A1 (ja) | 2007-09-26 | 2009-04-02 | Chugai Seiyaku Kabushiki Kaisha | 抗体定常領域改変体 |
| EP3127921A1 (en) | 2007-09-26 | 2017-02-08 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substition in cdr |
| AR068767A1 (es) | 2007-10-12 | 2009-12-02 | Novartis Ag | Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina |
| PL2567709T3 (pl) | 2007-11-02 | 2018-06-29 | Novartis Ag | Cząsteczki i sposoby modulowania białka związanego z receptorem dla lipoproteiny o niskiej gęstości 6 (LRP6) |
| RU2541780C2 (ru) | 2007-12-05 | 2015-02-20 | Чугаи Сейяку Кабусики Кайся | Терапевтическое средство от зуда |
| BRPI0821110B8 (pt) | 2007-12-05 | 2021-05-25 | Chugai Pharmaceutical Co Ltd | anticorpo de neutralização de anti-nr10/il31ra, composição farmacêutica compreendendo o referido anticorpo e uso do mesmo |
| CA2707400A1 (en) | 2007-12-14 | 2009-06-25 | Amgen Inc. | Method for treating bone fracture with anti-sclerostin antibodies |
| HUE067049T2 (hu) | 2008-04-11 | 2024-09-28 | Chugai Pharmaceutical Co Ltd | Két vagy több antigén-molekulát ismétlõdõen megkötni képes antigénkötõ molekula |
| CA2735193A1 (en) * | 2008-08-26 | 2010-03-11 | Macrogenics, Inc. | T-cell receptor antibodies and methods of use thereof |
| US20100082438A1 (en) * | 2008-10-01 | 2010-04-01 | Ronnie Jack Garmon | Methods and systems for customer performance scoring |
| JP5139517B2 (ja) * | 2008-12-05 | 2013-02-06 | 中外製薬株式会社 | 抗ｎｒ１０抗体、およびその利用 |
| KR20160062207A (ko) * | 2008-12-05 | 2016-06-01 | 추가이 세이야쿠 가부시키가이샤 | 항ｎｒ１０ 항체 및 그의 이용 |
| JP2010210772A (ja) * | 2009-03-13 | 2010-09-24 | Dainippon Screen Mfg Co Ltd | 液晶表示装置の製造方法 |
| US9228017B2 (en) | 2009-03-19 | 2016-01-05 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
| EP3674317B1 (en) | 2009-03-19 | 2024-12-11 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
| PT2896404T (pt) * | 2009-06-04 | 2017-10-24 | Novartis Ag | Método de identificação de sítios para conjugação de igg |
| US8221753B2 (en) | 2009-09-30 | 2012-07-17 | Tracon Pharmaceuticals, Inc. | Endoglin antibodies |
| AU2010284433B2 (en) * | 2009-08-17 | 2013-12-05 | Health Research, Inc. | Combination therapy of cancer with anti-endoglin antibodies and anti-VEGF agents |
| CA2787074A1 (en) * | 2010-01-19 | 2011-07-28 | Immunomedics, Inc. | Novel antibodies that target the insulin-like growth factor type i receptor (igf-1r) |
| CN112480256A (zh) | 2010-05-04 | 2021-03-12 | 戊瑞治疗有限公司 | 结合csf1r的抗体 |
| SMT202000095T1 (it) | 2010-05-14 | 2020-03-13 | Amgen Inc | Formulazioni di anticorpi anti-sclerostina ad alta concentrazione |
| JP2014503482A (ja) | 2010-11-05 | 2014-02-13 | ノバルティス アーゲー | Ｉｌ−１７アンタゴニストを用いて関節リウマチを治療する方法 |
| CN103328632A (zh) | 2010-11-30 | 2013-09-25 | 中外制药株式会社 | 与多分子的抗原重复结合的抗原结合分子 |
| US9133272B2 (en) | 2011-03-01 | 2015-09-15 | Amgen Inc. | Bispecific binding agents |
| BR112013024493A2 (pt) * | 2011-03-25 | 2018-06-26 | Amgen Inc. | cristais de anticorpo antiesclerostina e formulações dos mesmos |
| LT2699261T (lt) | 2011-04-19 | 2018-11-12 | Amgen Inc. | Osteoporozės gydymo būdas |
| JP2014515759A (ja) | 2011-04-29 | 2014-07-03 | ノバルティス アーゲー | 扁平上皮がんを治療する方法関連出願 |
| HUE039786T2 (hu) | 2011-08-04 | 2019-02-28 | Amgen Inc | Csonthiány-defektusok kezelési módszere |
| EA202091676A1 (ru) | 2011-12-28 | 2021-01-29 | Эмджен Инк. | Способ лечения потери костной массы альвеолярного отростка посредством применения антител к склеростину |
| US20130302322A1 (en) | 2012-05-11 | 2013-11-14 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| CN104619342A (zh) | 2012-07-05 | 2015-05-13 | Ucb医药有限公司 | 骨疾病的治疗 |
| US10431325B2 (en) | 2012-08-03 | 2019-10-01 | Novartis Ag | Methods to identify amino acid residues involved in macromolecular binding and uses therefor |
| CA2882804A1 (en) | 2012-08-31 | 2014-03-06 | Brian Wong | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| UA115789C2 (uk) | 2012-09-05 | 2017-12-26 | Трейкон Фармасутікалз, Інк. | Композиція антитіла до cd105 та її застосування |
| UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
| WO2014118705A1 (en) | 2013-01-31 | 2014-08-07 | Novartis Ag | Methods of treating chronic kidney disease-mineral and bone disorder using sclerostin antagonists |
| CA2901114C (en) | 2013-02-22 | 2020-01-07 | Medimmune Limited | Novel antibody conjugates and uses thereof |
| TWI636063B (zh) * | 2013-03-08 | 2018-09-21 | 美國禮來大藥廠 | 結合ｉｌ－２３之抗體 |
| WO2014144817A2 (en) | 2013-03-15 | 2014-09-18 | Amgen Inc. | Inhibitory polypeptides specific to wnt inhibitors |
| WO2014155278A2 (en) | 2013-03-26 | 2014-10-02 | Novartis Ag | Methods of treating autoimmune diseases using il-17 antagonists |
| MX377339B (es) | 2013-08-28 | 2025-03-06 | Abbvie Stemcentrx Llc | Metodos de conjugacion de anticuerpos especificos de sitio y composiciones. |
| WO2015127407A1 (en) | 2014-02-21 | 2015-08-27 | Stemcentrx, Inc. | Anti-dll3 antibodies and drug conjugates for use in melanoma |
| US10975153B2 (en) | 2014-06-23 | 2021-04-13 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) |
| CN114569716A (zh) | 2014-10-23 | 2022-06-03 | 美国安进公司 | 降低药物制剂的粘度 |
| LT3212670T (lt) | 2014-10-29 | 2021-02-10 | Five Prime Therapeutics, Inc. | Kombinuotasis vėžio gydymas |
| US9926375B2 (en) | 2014-11-12 | 2018-03-27 | Tracon Pharmaceuticals, Inc. | Anti-endoglin antibodies and uses thereof |
| US10155820B2 (en) | 2014-11-12 | 2018-12-18 | Tracon Pharmaceuticals, Inc. | Anti-endoglin antibodies and uses thereof |
| MA41142A (fr) | 2014-12-12 | 2017-10-17 | Amgen Inc | Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement |
| ES2843586T3 (es) | 2014-12-22 | 2021-07-19 | Five Prime Therapeutics Inc | Anticuerpos dirigidos contra CSF1R para tratar la SVNP |
| AR103173A1 (es) | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
| EP3782641A1 (en) * | 2015-03-13 | 2021-02-24 | Jiangsu Hengrui Medicine Co., Ltd. | Anti-sclerostin antibody, antigen binding fragment and medical use thereof |
| AU2016249981B2 (en) | 2015-04-13 | 2022-02-17 | Five Prime Therapeutics, Inc. | Combination therapy for cancer |
| JP5954916B1 (ja) | 2015-04-14 | 2016-07-20 | 中外製薬株式会社 | Ｉｌ−３１アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び／又は治療用医薬組成物 |
| TWI715587B (zh) | 2015-05-28 | 2021-01-11 | 美商安可美德藥物股份有限公司 | Ｔｉｇｉｔ結合劑和彼之用途 |
| JO3711B1 (ar) | 2015-07-13 | 2021-01-31 | H Lundbeck As | أجسام مضادة محددة لبروتين تاو وطرق استعمالها |
| CL2016000164A1 (es) * | 2016-01-21 | 2016-07-29 | Pontificia Universidad Católica De Chile | Anticuerpos monoclonales específicos para el antígeno piii de adenovirus humano (adv), producidos y secretados por hibridomas celulares, útiles para la detección y el diagnóstico de la infección causada por adv. |
| GB201604124D0 (en) | 2016-03-10 | 2016-04-27 | Ucb Biopharma Sprl | Pharmaceutical formulation |
| EA039540B1 (ru) * | 2016-03-25 | 2022-02-08 | Онкомед Фармасьютикалс, Инк. | Связывающие tigit агенты и варианты их применения |
| SI3484916T1 (sl) | 2016-07-12 | 2021-08-31 | H. Lundbeck A/S | Protitelesa, specifična za hiperfosforiliran Tau, in postopki za uporabo le-teh |
| AU2017310412A1 (en) | 2016-08-08 | 2019-02-21 | Amgen Inc. | Method of improving connective tissue attachment using anti-sclerostin antibodies |
| CN110662552A (zh) | 2016-11-30 | 2020-01-07 | 昂科梅德制药有限公司 | 包含tigit结合剂的癌症治疗方法 |
| CN110325548B (zh) | 2016-12-21 | 2023-11-17 | 美莱奥生物制药第三有限公司 | 抗硬化蛋白抗体在治疗成骨不全症中的用途 |
| US10961305B2 (en) | 2016-12-21 | 2021-03-30 | Mereo Biopharma 3 Limited | Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta |
| JP7191833B2 (ja) | 2017-01-30 | 2022-12-19 | 中外製薬株式会社 | 抗スクレロスチン抗体およびその使用 |
| JP7377596B2 (ja) | 2017-02-22 | 2023-11-10 | アムジエン・インコーポレーテツド | 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法 |
| ES3036143T3 (en) | 2017-04-28 | 2025-09-15 | Amgen Inc | N-acetylated and non-acetylated dipeptides containing arginine to reduce the viscosity of viscous compositions of therapeutic polypeptides |
| EP3662288B1 (en) | 2017-08-01 | 2024-02-28 | Amgen Inc. | Systems and methods for performing a real-time glycan assay of a sample |
| ES2978396T3 (es) | 2017-08-01 | 2024-09-11 | Amgen Inc | Sistemas y métodos para la preparación en tiempo real de una muestra de polipéptidos para el análisis por espectrometría de masas |
| MX2020002301A (es) | 2017-09-13 | 2020-07-13 | Five Prime Therapeutics Inc | Terapia de combinacion de anticuerpos anti receptor del factor estimulante de colonias 1 (csf1r) y anti proteina de muerte programada 1 (pd-1) combinados para cancer pancreatico. |
| ES2965064T3 (es) | 2018-03-13 | 2024-04-10 | Amgen Inc | Métodos para la preparación de polipéptidos resistentes a tripsina para análisis espectrométrico de masas |
| EP3765857B1 (en) | 2018-03-13 | 2025-12-10 | Amgen Inc. | Sequential digestion of polypeptides for mass spectrometric analysis |
| IL316596A (en) | 2018-03-30 | 2024-12-01 | Amgen Inc | C-terminal antibody variants |
| GB201810746D0 (en) | 2018-06-29 | 2018-08-15 | Mereo Biopharma 3 Ltd | Use of sclerostin antagonist |
| AU2019316575B2 (en) | 2018-08-10 | 2025-05-22 | Amgen Inc. | Method of preparing an antibody pharmaceutical formulation |
| AU2019396614B2 (en) | 2018-12-14 | 2025-07-10 | Amgen Inc. | System suitability method for use with protein concentration determination by slope |
| EP4397977A3 (en) | 2019-02-14 | 2024-09-11 | Amgen Inc. | Systems and methods for preparing a sample and performing a real-time assay of the sample |
| EP3928101B1 (en) | 2019-02-20 | 2024-10-09 | Amgen Inc. | Methods of determining protein stability |
| AU2020231509A1 (en) | 2019-03-04 | 2021-08-19 | Amgen Inc. | In vivo reversibility of high molecular weight species |
| JP7691931B2 (ja) | 2019-03-27 | 2025-06-12 | アムジェン インコーポレイテッド | 製剤化された生物製剤製品のための、天然存在比での二次元（２ｄ）核磁気共鳴技術によって治療用タンパク質をフィンガープリントする方法 |
| ES2997211T3 (en) | 2019-06-05 | 2025-02-14 | Amgen Inc | Methods of identifying attributes of therapeutic proteins |
| MX2022001805A (es) | 2019-08-12 | 2022-06-08 | Amgen Inc | Formulaciones de anticuerpos anti-esclerostina. |
| US12497446B2 (en) | 2019-08-13 | 2025-12-16 | The Feinstein Institutes For Medical Research | Tetranectin-targeting monoclonal antibodies to fight against lethal sepsis and other pathologies |
| IL293099B2 (en) | 2019-11-20 | 2025-07-01 | Chugai Pharmaceutical Co Ltd | Antibody-containing preparation |
| US20230349912A1 (en) | 2020-09-18 | 2023-11-02 | Amgen Inc. | Methods of processing a sample for peptide mapping analysis |
| MX2023005320A (es) | 2020-11-05 | 2023-05-19 | Amgen Inc | Materiales y metodos para el procesamiento de proteinas. |
| TW202325853A (zh) | 2021-11-09 | 2023-07-01 | 美商安進公司 | 治療性蛋白之生產 |
| CN121311767A (zh) | 2023-06-14 | 2026-01-09 | 百时美施贵宝公司 | 糖蛋白的近实时唾液酸定量 |
| AR133302A1 (es) | 2023-07-19 | 2025-09-17 | Amgen Inc | Métodos de preparación de amortiguador para una formulación de proteína terapéutica |
| WO2025101602A1 (en) | 2023-11-07 | 2025-05-15 | Amgen Inc. | Methods of analyzing amino acid content of a therapeutic protein |
| WO2025255028A1 (en) | 2024-06-03 | 2025-12-11 | Amgen Inc. | High-throughput liquid chromatography-mass spectrometry-based peptide mapping |
Family Cites Families (90)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US32011A (en) | 1861-04-09 | Coffee-pot | ||
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4411993A (en) | 1981-04-29 | 1983-10-25 | Steven Gillis | Hybridoma antibody which inhibits interleukin 2 activity |
| US4427115A (en) | 1981-10-19 | 1984-01-24 | Laipply Thomas C | One piece alcohol preparation device |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| USRE32011E (en) | 1981-12-14 | 1985-10-22 | Scripps Clinic And Research Foundation | Ultrapurification of factor VIII using monoclonal antibodies |
| JPS58117537A (ja) | 1982-01-06 | 1983-07-13 | Toray Ind Inc | 感光性樹脂組成物 |
| US4543439A (en) | 1982-12-13 | 1985-09-24 | Massachusetts Institute Of Technology | Production and use of monoclonal antibodies to phosphotyrosine-containing proteins |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| US6054561A (en) | 1984-02-08 | 2000-04-25 | Chiron Corporation | Antigen-binding sites of antibody molecules specific for cancer antigens |
| DE3417525C1 (de) | 1984-05-11 | 1986-01-09 | Matter + Siegmann Ag, Wohlen | Vorrichtung zur quantitativen und qualitativen Erfassung von kohlenwasserstoffhaltigen Schwebeteilchen in Gasen |
| US4902614A (en) | 1984-12-03 | 1990-02-20 | Teijin Limited | Monoclonal antibody to human protein C |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5549910A (en) | 1989-03-31 | 1996-08-27 | The Regents Of The University Of California | Preparation of liposome and lipid complex compositions |
| US5177197A (en) | 1990-02-27 | 1993-01-05 | Ludwig Institute For Cancer Research | Isolated nucleotide sequence expressing human transforming growth factor-β1-binding protein |
| US5466468A (en) | 1990-04-03 | 1995-11-14 | Ciba-Geigy Corporation | Parenterally administrable liposome formulation comprising synthetic lipids |
| US5837456A (en) * | 1990-06-11 | 1998-11-17 | Nexstar Pharmaceuticals, Inc. | High affinity oligonucleotide ligands to chorionic gonadotropin hormone and related glycoprotein hormones |
| JP3218637B2 (ja) | 1990-07-26 | 2001-10-15 | 大正製薬株式会社 | 安定なリポソーム水懸濁液 |
| EP0542810A1 (en) | 1990-08-02 | 1993-05-26 | B.R. Centre Limited | Methods for the production of proteins with a desired function |
| JP2958076B2 (ja) | 1990-08-27 | 1999-10-06 | 株式会社ビタミン研究所 | 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法 |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
| JPH04141095A (ja) | 1990-10-02 | 1992-05-14 | Chemo Sero Therapeut Res Inst | 組換え抗ｈｉｖ改変抗体および改変抗体の調製方法 |
| US5070108A (en) | 1990-10-12 | 1991-12-03 | Trustees Of The University Of Pennsylvania | Methods of treating osteoporosis, increasing bone mineral content and preventing the occurrence of compression fractures in a mammal |
| AU662304B2 (en) | 1990-10-22 | 1995-08-31 | Fox Chase Cancer Center | DNA construct for providing RNA therapy |
| US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| JP3370324B2 (ja) | 1991-04-25 | 2003-01-27 | 中外製薬株式会社 | ヒトインターロイキン−６受容体に対する再構成ヒト抗体 |
| EP0708659A4 (en) | 1993-06-07 | 2000-08-23 | Genentech Inc | HIV ENVELOPE POLYPEPTIDES |
| US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
| US5453492A (en) | 1993-07-28 | 1995-09-26 | La Jolla Cancer Research Foundation | 60 kDa transforming growth factor-β-binding protein and its use to detect or purify TGF-β |
| US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| US5837458A (en) | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
| AU702163B2 (en) | 1994-04-29 | 1999-02-18 | Creative Biomolecules, Inc. | Morphogenic protein-specific cell surface receptors and uses therefor |
| US5846770A (en) | 1994-11-22 | 1998-12-08 | Genetics Institute, Inc. | DNA molecules encoding human chordin |
| US6057421A (en) | 1994-11-30 | 2000-05-02 | Immpheron, Inc. | Variable heavy and light chain regions of murine monoclonal antibody 1F7 |
| US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| IE80468B1 (en) | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
| CA2220912A1 (en) | 1995-06-05 | 1996-12-12 | Gregg A. Hastings | Human ccn-like growth factor |
| US5738868A (en) | 1995-07-18 | 1998-04-14 | Lipogenics Ltd. | Liposome compositions and kits therefor |
| ES2312177T3 (es) | 1996-05-22 | 2009-02-16 | Viventia Biotech Inc. | Fragmentos de union a antigenos que detectan especificamente celulas cancerosas, nucleotidos que codifican los fragmentos y el uso de los mismos para la profilaxis y deteccion de canceres. |
| US6133426A (en) | 1997-02-21 | 2000-10-17 | Genentech, Inc. | Humanized anti-IL-8 monoclonal antibodies |
| US5989909A (en) | 1997-09-26 | 1999-11-23 | Millennium Biotherapeutics, Inc. | Huchordin and uses thereof |
| US6117911A (en) | 1997-04-11 | 2000-09-12 | Neorx Corporation | Compounds and therapies for the prevention of vascular and non-vascular pathologies |
| DE69839147T2 (de) | 1997-06-12 | 2009-02-19 | Novartis International Pharmaceutical Ltd. | Künstliche antikörperpolypeptide |
| US6075007A (en) | 1997-07-17 | 2000-06-13 | Regeneron Pharmaceuticals, Inc. | Modified noggin polypeptide and compositions |
| JP2001512016A (ja) | 1997-08-01 | 2001-08-21 | ジェンセット | 筋肉およびその他中胚葉組織中で発現される分泌タンパク質の５’ｅｓｔ |
| US6815201B2 (en) | 1997-09-08 | 2004-11-09 | The Public Health Research Institute Of The City Of New York, Inc. | HIV-1 gp120 V1/V2 domain epitopes capable of generating neutralizing antibodies |
| US6544485B1 (en) | 2001-01-29 | 2003-04-08 | Sharper Image Corporation | Electro-kinetic device with enhanced anti-microorganism capability |
| HK1044171B (zh) | 1998-11-27 | 2016-03-24 | Ucb Pharma S.A. | 增加骨矿化的组合物和方法 |
| US20040009535A1 (en) * | 1998-11-27 | 2004-01-15 | Celltech R&D, Inc. | Compositions and methods for increasing bone mineralization |
| EP1657256B1 (en) | 1999-06-09 | 2009-10-07 | Genentech, Inc. | Compositions and methods for the treatment of tumor |
| MXPA02008506A (es) | 2000-03-02 | 2002-12-13 | Amgen Inc | Moleculas semejantes a chordin-2 y sus usos. |
| MXPA02011808A (es) | 2000-06-01 | 2003-04-10 | Amgen Inc | Polipeptidos de nudos de cistinas: moleculas de polipeptidos encubierto-2 y usos de los mismos. |
| US20040132021A1 (en) | 2000-06-19 | 2004-07-08 | Wendy Balemans | Osteolevin gene polymorphisms |
| CA2421056A1 (en) | 2000-09-01 | 2002-03-28 | Genentech, Inc. | A polypeptide for use as a diagnostic marker for the presence of colon tumours |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| CA2374027A1 (en) | 2001-03-13 | 2002-09-13 | The Minister Of National Defence | Cloning, expression, sequencing, and functional enhancement of monoclonal scfv antibody against venezuelan equine encephalitis virus(vee) |
| WO2003050513A2 (en) | 2001-12-06 | 2003-06-19 | Biocontrol Systems, Inc. | Sample collection and testing system |
| US20030186915A1 (en) | 2002-02-11 | 2003-10-02 | Yang Pan | Regulatory polynucleotides and uses thereof |
| AU2003223214B2 (en) | 2002-03-01 | 2008-09-18 | Celltech R & D, Inc. | Methods to increase or decrease bone density |
| US7799523B2 (en) | 2002-04-03 | 2010-09-21 | Celltech R & D, Inc. | Association of polymorphisms in the SOST gene region with bone mineral density |
| FR2838379B1 (fr) | 2002-04-12 | 2005-06-24 | Valeo Climatisation | Dispositif de purification de l'air de l'habitacle d'un vehicule automobile |
| AU2003276430A1 (en) | 2002-06-14 | 2003-12-31 | Stowers Institute For Medical Research | Wise/sost nucleic acid sequences and amino acid sequences |
| US7893218B2 (en) | 2003-06-16 | 2011-02-22 | Stowers Institute For Medical Research | Antibodies that specifically bind SOST peptides |
| EP1572122A4 (en) | 2002-11-01 | 2008-04-09 | Us Gov Health & Human Serv | METHOD FOR PREVENTING INFECTIONS OF BIOTERRORISM AGENTS WITH IMMUNOSTIMULATING CPG OLIGONUCLEOTIDES |
| DE10255152A1 (de) | 2002-11-26 | 2004-06-03 | Von Langen Ursula Lang | Schadstoffsauger |
| FI115753B (fi) | 2002-11-29 | 2005-07-15 | Paloheimo Raija | Menetelmä ja sovitelma kahvijuomien valmistamiseksi |
| US7642238B2 (en) | 2002-12-05 | 2010-01-05 | Shaughnessy John D | Molecular determinants of myeloma bone disease and uses thereof |
| US20040141875A1 (en) | 2003-01-15 | 2004-07-22 | Rajiv Doshi | System and method for treating microorganisms within motor vehicle heating, ventilation, and air conditioning units |
| US7226902B2 (en) | 2003-03-14 | 2007-06-05 | Celltech R&D, Inc. | Ligands for TGF-beta binding proteins and uses thereof |
| CU23403A1 (es) | 2003-04-23 | 2009-08-04 | Centro Inmunologia Molecular | Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores |
| AU2004262640B2 (en) | 2003-06-16 | 2010-12-23 | Ucb Manufacturing, Inc. | Antibodies specific for sclerostin and methods for increasing bone mineralization |
| US8461155B2 (en) | 2003-09-22 | 2013-06-11 | University Of Connecticut | Sclerostin and the inhibition of WNT signaling and bone formation |
| US7592429B2 (en) | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
| US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
| WO2008133722A2 (en) | 2006-11-10 | 2008-11-06 | Ucb Pharma S.A. | Anti human sclerostin antibodies |
| EP2097450A2 (en) | 2006-11-10 | 2009-09-09 | Amgen Inc. | Antibody-based diagnostics and therapeutics |
| NZ578235A (en) | 2007-02-02 | 2012-05-25 | Novartis Ag | Modulators of sclerostin binding partners for treating bone-related disorders |
| PT2131860E (pt) | 2007-03-20 | 2014-03-04 | Lilly Co Eli | Anticorpos antiesclerostina |
| CL2008002775A1 (es) | 2007-09-17 | 2008-11-07 | Amgen Inc | Uso de un agente de unión a esclerostina para inhibir la resorción ósea. |
| AR068767A1 (es) | 2007-10-12 | 2009-12-02 | Novartis Ag | Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina |
| PL2567709T3 (pl) | 2007-11-02 | 2018-06-29 | Novartis Ag | Cząsteczki i sposoby modulowania białka związanego z receptorem dla lipoproteiny o niskiej gęstości 6 (LRP6) |
| CA2707400A1 (en) | 2007-12-14 | 2009-06-25 | Amgen Inc. | Method for treating bone fracture with anti-sclerostin antibodies |
-
2006
- 2006-04-25 US US11/410,540 patent/US8003108B2/en active Active
- 2006-04-28 EP EP06751835A patent/EP1891100A2/en not_active Withdrawn
- 2006-04-28 ES ES10014373T patent/ES2624643T5/es active Active
- 2006-04-28 HU HUE10014373A patent/HUE032092T2/en unknown
- 2006-04-28 CA CA2607276A patent/CA2607276C/en active Active
- 2006-04-28 FI FIEP10014373.4T patent/FI2301961T4/fi active
- 2006-04-28 EP EP10014360.1A patent/EP2345668B1/en active Active
- 2006-04-28 HR HRP20170679TT patent/HRP20170679T4/hr unknown
- 2006-04-28 LT LTEP10014373.4T patent/LT2301961T/lt unknown
- 2006-04-28 JP JP2008510081A patent/JP5680823B2/ja active Active
- 2006-04-28 SI SI200632158T patent/SI2251351T2/sl unknown
- 2006-04-28 PL PL10014373.4T patent/PL2301961T5/pl unknown
- 2006-04-28 WO PCT/US2006/016345 patent/WO2006119062A2/en not_active Ceased
- 2006-04-28 EP EP10006930.1A patent/EP2251351B2/en active Active
- 2006-04-28 HR HRP20170514TT patent/HRP20170514T4/hr unknown
- 2006-04-28 DK DK10014373.4T patent/DK2301961T4/da active
- 2006-04-28 MY MYPI20093533A patent/MY174493A/en unknown
- 2006-04-28 ES ES10014372T patent/ES2620684T5/es active Active
- 2006-04-28 FI FIEP10006930.1T patent/FI2251351T4/fi active
- 2006-04-28 EP EP10014372.6A patent/EP2295448B2/en active Active
- 2006-04-28 SI SI200632170T patent/SI2301961T2/sl unknown
- 2006-04-28 PT PT100069301T patent/PT2251351T/pt unknown
- 2006-04-28 EP EP10014361.9A patent/EP2298800B9/en active Active
- 2006-04-28 PL PL10006930.1T patent/PL2251351T5/pl unknown
- 2006-04-28 DK DK10006930.1T patent/DK2251351T4/da active
- 2006-04-28 LT LTEP10006930.1T patent/LT2251351T/lt unknown
- 2006-04-28 HU HUE10006930A patent/HUE033718T2/en unknown
- 2006-04-28 MX MX2011003958A patent/MX348432B/es unknown
- 2006-04-28 ES ES10014361T patent/ES2616985T5/es active Active
- 2006-04-28 ES ES10014360T patent/ES2901698T3/es active Active
- 2006-04-28 ES ES10006930T patent/ES2619709T5/es active Active
- 2006-04-28 EP EP10014373.4A patent/EP2301961B9/en active Active
- 2006-04-28 PT PT100143734T patent/PT2301961T/pt unknown
-
2011
- 2011-04-28 US US13/096,263 patent/US8715663B2/en active Active
-
2014
- 2014-02-20 US US14/185,590 patent/US9353174B2/en active Active
- 2014-05-07 JP JP2014095921A patent/JP2014177470A/ja active Pending
-
2015
- 2015-09-30 JP JP2015192869A patent/JP6158268B2/ja active Active
-
2017
- 2017-02-23 JP JP2017031654A patent/JP2017128583A/ja active Pending
- 2017-03-31 CY CY20171100393T patent/CY1118977T1/el unknown
- 2017-05-09 CY CY20171100495T patent/CY1119127T1/el unknown
-
2018
- 2018-08-06 JP JP2018147689A patent/JP6858733B2/ja active Active
-
2020
- 2020-05-07 JP JP2020081948A patent/JP7010994B2/ja active Active
-
2021
- 2021-12-01 JP JP2021195517A patent/JP7361086B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020122011A5 (member.php) | ||
| ME02085B (me) | Sklerostin vezujuća sredstva | |
| HRP20170679T1 (hr) | Epitopi sklerostina | |
| JP2015524256A5 (member.php) | ||
| HRP20201438T1 (hr) | Metoda inhibiranja resorpcije kosti | |
| JP2023113836A5 (member.php) | ||
| JP2017505622A5 (member.php) | ||
| RU2009108147A (ru) | Иммуноглобулины | |
| JP2010524489A5 (member.php) | ||
| RU2010141584A (ru) | Антитело против csf-1r | |
| HRP20201266T1 (hr) | Anti fg23 antitijelo i farmaceutski pripravak koji sadrži isto | |
| JP2018524577A5 (member.php) | ||
| MA31308B1 (fr) | Anticorps antisclerostine. | |
| TW200412982A (en) | Method for promoting bone formation | |
| EP3345925A3 (en) | Humanized antibodies targeting the ec1 domain of cadherin-11 and related compositions and methods | |
| JP2011502137A5 (member.php) | ||
| RU2016122340A (ru) | Il-17a-связующий агент и способы его применения | |
| JP2023093753A5 (member.php) | ||
| JP2005506331A5 (member.php) | ||
| JP2011522856A (ja) | （４−｛［（５−｛［（３−クロロフェニル）メチル］オキシ｝−２−メチルフェニル）カルボニル］アミノ｝−３−メチルフェニル）酢酸の新規な塩 | |
| Yuan et al. | Ridge preservation applying a novel hydrogel for early angiogenesis and osteogenesis evaluation: an experimental study in canine | |
| JP2014501513A5 (member.php) | ||
| HRP20241557T1 (hr) | Proteini koji vezuju receptor aktivina tipa 2 i njihova uporaba | |
| JP2009515994A5 (member.php) | ||
| JP2023182691A5 (member.php) |